Navigation Links
Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
Date:10/4/2007

HOPKINTON, Mass., Oct. 4 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that Kenneth Rice, Jr., Executive Vice President and Chief Financial Officer of Alseres Pharmaceuticals, Inc., will be presenting a Company overview at the BIO Investor Forum 2007 Wednesday, October 10, 2007 at 5:15pm PDT in San Francisco, CA. This national investor forum sponsored by the Biotechnology Industry Organization is being held on October 9-11 at the Palace Hotel in San Francisco, CA. The presentation will be web cast live at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=ALSE&item_id=16 and available on our investor web site for replay at http://www.alseres.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

The BIO Investor Forum is a national investor forum to explore investment trends and opportunities in life sciences, with a focus on public and venture-stage growth companies as well as those poised to join the growth "watch list" in 2008.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) is a biotechnology company engaged in developing breakthrough regenerative therapeutics to treat traumatic injuries and degenerative diseases. The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. Our energy and focus is reflected in several important initiatives. Cethrin(R) is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. Cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. ALTROPANE(R), the lead molecular imaging candidate, is in Phase III clinical trials for the diagnosis of Parkinson's disease. Alseres has research collaborations with Harvard Medical School and Children's Hospital Boston.

Contact: Sharon Correia

Director, Corporate Communications

scorreia@alseres.com

508-497-2360 ext. 224


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... they will feature Federal Hybrids, Inc. in an upcoming episode, scheduled to broadcast ... American Farmer will explore Federal Hybrids, the independent, family-owned seed company. Educating audiences ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... for the Semiconductor, MEMS, and Microfluidics Industries, announces the new Model 800E front ... more often in automated production mask aligners. OAI has already received and ...
(Date:8/17/2017)... Springs, FL (PRWEB) , ... August 17, 2017 ... ... announced that the stock market news outlet had provided a research update on ... company's nasally administered TRT product. , According to Soulstring, prescription rates for Natesto® ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... cancer research and personalized medicine, today announced the launch of a new breast ... Missouri. The study’s goal is to evaluate the potential for early detection of ...
Breaking Biology Technology:
(Date:8/15/2017)... 2017   ivWatch LLC , a medical device company focused ... announced receipt of its ISO 13485 Certification, the global standard for ... for Standardization (ISO®). ... 400 Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, ...
(Date:7/20/2017)... Delta (NYSE: DAL ) customers now can use fingerprints instead ... National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in ... the boarding process to allow eligible Delta SkyMiles Members who are enrolled ...
(Date:6/30/2017)... , June 30, 2017 Today, American ... and supplier of face and eye tracking software, ... Product provider program. "Artificial intelligence ... way to monitor a driver,s attentiveness levels while ... being able to detect fatigue and prevent potential ...
Breaking Biology News(10 mins):